Build­ing on suc­cess­ful PD-1 pact, Eli Lil­ly li­cens­es di­a­betes drug to Chi­nese part­ners at In­novent

Eli Lil­ly is ex­pand­ing its part­ner­ship with Chi­na’s In­novent in a deal in­volv­ing a di­a­betes drug sit­ting in its Phase I re­serves.

The two com­pa­nies …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.